aap Implantate AG

Board/Management Information • Nov 28, 2008

News Details

Ad-hoc | 28 November 2008 08:01

aap Implantate AG: Management Board Changes at aap Implantate AG: Biense Visser New CEO

aap Implantate AG / Change of Personnel

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

aap Implantate AG, a medical technology company listed on the Frankfurt
stock exchange in the Prime Standard segment, has named Biense Visser, 56,
currently a member of aap’s Supervisory Board and CEO of the Dutch company
De Ruiter Seeds B.V., as the new chief executive officer of aap Implantate
AG. Today, the Supervisory Board appointed him as a member of the
Management Board and, with effect from January 1, 2009, as the Board’s
chairman. In addition to his work as CEO, Mr. Visser will also be in charge
of Finance. Biense Visser is a Dutch citizen, studied pharmacy, holds an
MBA and has many years’ experience as a CEO of various pharmaceutical and
healthcare companies. In taking up his appointment at aap, Mr. Visser will
stand down as Board Chairman of De Ruiter Seeds B.V., Bergschenhoek, The
Netherlands.

His place on aap’s Supervisory Board will be taken by Ronald Meersschaert,
46, who was elected as a substitute member of the Supervisory Board at the
last Annual General Meeting. Mr. Meersschaert is currently a partner in the
private equity company Boekhoorn M. & A. B.V., Arnhem, The Netherlands.

With effect from December 1, 2008, the Supervisory Board named Bruke Seyoum
Alemu as Chief Operating Officer. In this function he will be as a member
of the Management Board in charge of Development, Production, Sales and
Marketing at the aap Group.

Oliver Bielenstein is leaving by mutual agreement as of December 31, 2008,
as the company’s CFO and Board member in charge of the medical biomaterials
division. Mr. Bielenstein will continue to be at aap’s service as a
consultant.

The Management Board and Supervisory Board of aap Implantate AG would like
to thank Mr. Bielenstein for his commitment over the past four years and
for successfully developing the Group’s biomaterials division.

Contact:
Bei Rückfragen wenden Sie sich bitte an:
aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications &
Legal Affairs; Lorenzweg 5; D-12099 Berlin
Tel.: ++49/30/750 19 – 133; Fax.: ++49/30/750 19 – 290; n.huedepohl@aap.de

28.11.2008 Financial News transmitted by DGAP

Language: English
Issuer: aap Implantate AG
Lorenzweg 5
12099 Berlin
Deutschland
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: aap@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Hannover, Düsseldorf, Hamburg, München, Stuttgart

End of News DGAP News-Service

---